Akebia Therapeutics (AKBA) Goodwill (2018 - 2026)

Akebia Therapeutics (AKBA) has 9 years of Goodwill data on file, last reported at $59.0 million in Q1 2026.

• On a quarterly basis, Goodwill changed 0.0% year-over-year to $59.0 million in Q1 2026; TTM through Mar 2026 was $59.0 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $59.0 million, changed 0.0% from the prior year.
• Goodwill for Q1 2026 stood at $59.0 million, roughly flat from $59.0 million in the prior quarter.
• Over the last five years, Goodwill for AKBA reached as high as $59.0 million in Q1 2022 and fell as low as $59.0 million in Q4 2022.
• Historically, Goodwill has averaged $59.0 million across 5 years, with a median of $59.0 million in 2022.
• Across the five-year window, Goodwill grew 7.25% in 2022 and decreased 0.07% in 2023, its largest moves.
• Year by year, Goodwill stood at $59.0 million in 2022, then climbed by 0.07% to $59.0 million in 2023, then changed by 0.0% to $59.0 million in 2024, then changed by 0.0% to $59.0 million in 2025, then changed by 0.0% to $59.0 million in 2026.
• Per Business Quant data, the three most recent Goodwill figures were $59.0 million in Q1 2026, $59.0 million in Q4 2025, and $59.0 million in Q3 2025.